# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN-TD
- Date: 1974-09-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review after the Las Vegas engagement and a back strain, before a three-week tour. **S**

## History of present illness

Mr. Presley returns after a three-week engagement in Las Vegas and two weeks after the sick visit for a back strain. The back pain settled within a week on split buprenorphine doses and naproxen, and he has gone back to 16 mg once each morning. He took no other opioid and no extra diazepam. He had video visits in the first and third weeks of the engagement; the second was missed when a rehearsal ran late, and a nurse called him the next day. He used the travel CPAP on most nights. He has had mild nausea for a day after each tirzepatide dose and no constipation. His weight is 105.1 kg. His ophthalmologist saw him last week, found his eye pressures controlled on latanoprost and made no change. His HIV and hepatitis C tests were nonreactive and his hepatitis B tests showed no immunity. The tour begins in four days. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily; no other opioid; cravings rare |
| Diazepam | 36 mg a day since the three-week visit; no withdrawal symptoms |
| Back strain | Resolved |
| Tirzepatide | 2.5 mg weekly for six weeks; mild nausea for a day after each dose |
| Weight | 105.1 kg, down 3.9 kg from intake |
| Ophthalmology | Pressures controlled; no change |
| Screening results | HIV and hepatitis C nonreactive; hepatitis B not immune |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good |
| Musculoskeletal | Negative | Back pain resolved |
| Gastrointestinal | Positive | Mild nausea for a day after each injection; bowels regular |
| Eyes | Negative | No pain or halos |
| Psychiatric | Negative | PHQ-9 5; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time **S**
- Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) **S**
- Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**
- Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/80 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 105.1 kg; BMI 31.4 kg/m². All vital signs are synthetic.

PHQ-9: 5; GAD-7: 7. All results are synthetic.

## Change since baseline

- PHQ-9: 8 at baseline, 5 at this visit **S**
- GAD-7: 9 at baseline, 7 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunity **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/80, pulse 74; weight 105.1 kg, BMI 31.4 |
| Back | Full, painless range of motion |
| Neurological | No tremor or sedation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). Stable through an engagement and an acute pain episode without other opioid use. Urine drug test today: buprenorphine and norbuprenorphine and benzodiazepines present, no other opioid and no fentanyl. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the tour bag. **S**
   - Continue 16 mg daily; tour prescriptions to the same named pharmacy chain.
   - Video visits weekly on tour at a fixed time with a backup slot.
2. **Benzodiazepine use disorder on a diazepam taper** (F13.20). Six weeks at 36 mg without withdrawal; a step now, four days before the tour, was discussed; he preferred to take it today and agreed to hold if he has symptoms. **S**
   - Diazepam 32 mg a day (10 mg three times daily with 2 mg once daily).
3. **Obesity, class 1, with prediabetes** (E66.811). Down 3.9 kg (3.6%) with mild nausea only. **S**
   - Tirzepatide increased to 5 mg weekly.
4. **Acute low back strain** (S39.012A). Resolved without imaging; naproxen finished. **S**
   - Warm up before karate.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every visit; weekly contact in the first month | Completed today | 16 mg daily; split dosing for one week during the back strain; no other opioid |
| Survey | Weekly video visits while away | Weekly during engagements and tours | Deferred | The second weekly video visit in Las Vegas was missed when a rehearsal ran late; a nurse reached him by phone the next day and found him well. No harm resulted. Corrective action: a fixed weekly time on tour with a backup slot the same day |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions, filled at the named pharmacies |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Completed today | Collected at the start of the visit: buprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative) |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | In the tour bag; two people trained |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | 36 to 32 mg a day (11%) after six weeks at 36 mg; no withdrawal symptoms |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms and medicines locked |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At each review | Completed today | PHQ-9 5 (item 9 scored 0); GAD-7 7 |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 126/80; home average 124/80 |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Up to date | Normal three weeks after starting; next at six months |
| Examination | Weight and BMI | Every visit | Completed today | 105.1 kg, BMI 31.4; down 3.9 kg |
| Medication safety | Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain | At each dose step | Completed today | Mild nausea for a day after each dose; no vomiting or constipation; increased to 5 mg |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Completed today | 86% of nights over the engagement; Epworth 7 |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Daily or every other day on polyethylene glycol |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | Ophthalmology last week: pressures controlled, no change; no new drug that affects eye pressure |
| Self-management | Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement | Before each engagement or tour | Completed today | Tour plan written: named pharmacy chain, fixed video visit time with backup, travel CPAP, naloxone |

## Goal progress

- Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal. Outcome by 1974-08-07: Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low. **S**
- One prescriber and one pharmacy for all controlled medicines. Outcome by 1974-09-23: Monitoring program shows only this clinic's prescriptions since intake. **S**
- Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping. In progress; target 1974-10-28. **S**
- Home blood pressure below 130/80. Outcome by 1974-08-07: Home average 146/94 to 126/80 on amlodipine and valsartan. **S**
- Lose 5% or more of body weight. In progress; target 1974-10-28. **S**
- CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness. In progress; target 1974-10-28. **S**
- A bowel movement at least every two days without straining. Outcome by 1974-08-07: Every one to two days on buprenorphine and polyethylene glycol. **S**

## Medication changes

- Stopped: Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly **S**
- Started: Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022), American Gastroenterological Association (Gastroenterology 2022;163(5):1198-1225)
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019), American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2020), American Academy of Ophthalmology (Ophthalmology 2021;128(1):P71-P150)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- First hepatitis B vaccine dose given today. Weekly video visits on tour. Four-month review after the tour. **S**
- Next scheduled visit 1974-10-28: four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead. **S**
